Last updated: April 25, 2026
Who Supplies Abiraterone Acetate for Pharmaceutical Use?
Abiraterone acetate is a regulated oncology API. Commercial supply is typically organized through (1) originator and licensed manufacturers of the API, and (2) contract manufacturers that formulate and package finished dosage forms. Because abiraterone acetate is widely used across mCRPC treatment lines, supply networks include both multinational API producers and generics/brands with distinct manufacturing authorizations.
Which Companies Supply Abiraterone Acetate (API) at Scale?
The following suppliers are consistently named in regulatory and market documentation for abiraterone acetate API supply chains.
API manufacturing suppliers (widely used in market authorizations)
| Supplier |
Role in supply chain |
Typical footprint |
| Apotex Inc. |
API and/or intermediate supplier for generic markets |
North America and licensed export supply |
| Bayer |
Originator supply for branded product ecosystem |
Global branded and downstream manufacturing |
| Cipla |
API/finished dosage ecosystem supplier |
India-based global generics |
| Dr. Reddy’s Laboratories |
API/finished dosage ecosystem supplier |
India-based global generics |
| Hetero Drugs |
API and/or finished dosage supplier |
India-based generics and exports |
| Hikma Pharmaceuticals |
API/finished dosage ecosystem supplier |
Global generics footprint |
| Mylan (now Viatris) |
Finished dosage and generics ecosystem supplier |
Large-volume global generics |
| Sun Pharmaceutical Industries |
API/finished dosage ecosystem supplier |
India-based global generics |
| Teva |
Finished dosage and generics ecosystem supplier |
Large-volume global generics |
Which Manufacturers Supply Finished Dosage Forms (Brand and Generic Tablets)?
Abiraterone acetate finished dosage forms are supplied through NDA/BLA or ANDA-backed generic programs, with packaging and batch release performed under site-specific regulatory authorizations.
Finished dosage form supply (generic and brand ecosystem)
| Company |
Finished dosage ecosystem |
Market role |
| Bayer |
Branded tablets |
Originator ecosystem |
| Mylan/Viatris |
Generic tablets |
High-volume supply |
| Teva |
Generic tablets |
Large established distribution |
| Cipla |
Generic tablets |
Broad export footprint |
| Dr. Reddy’s |
Generic tablets |
Large global generics footprint |
| Sun Pharma |
Generic tablets |
High-volume generics |
| Hikma |
Generic tablets |
Commercial generics supply |
| Hetero |
Generic tablets |
Exports and regional supply |
What Supplier Selection Criteria Drive Regulatory and Commercial Approval?
For high-stakes procurement in oncology APIs, the supplier choice is governed by the ability to produce consistent quality under GMP and to satisfy dossier-level expectations (spec, analytical methods, stability, impurity control).
Core supplier qualification checkpoints
- GMP status and inspection history for API manufacturing and finished product manufacturing sites
- Analytical method capability for assay, impurities, and residual solvents
- Stability package readiness aligned to the target market filing strategy
- Traceability for starting materials and intermediates used in the abiraterone acetate process
- Batch release performance across the supply horizon (lead time, yield, rejection rates)
Where the Supply Chain Typically Gets Bottlenecked
Abiraterone acetate programs face supply fragility primarily at two points: (1) the API and key intermediate manufacturing capacity, and (2) regulatory site readiness for ANDA/BLA filings in target markets. Brand ecosystems can also tighten supply during high-demand periods due to synchronized demand across geographies.
Common bottleneck points
- API/intermediate capacity tied to dedicated reactor and purification trains
- QA/QC release bandwidth during peak batch schedules
- Tight impurity specs requiring consistent upstream control
How to Operationalize Abiraterone Acetate Supplier Mapping (Actionable Framework)
A defensible supplier map for procurement or investment screening should be structured around three layers: regulatory authorization, site-specific capability, and commercial throughput.
Layer 1: Authorization mapping
- Identify which companies are listed as applicants or manufacturers in each major market’s approval records
- Capture named API and finished dosage manufacturing sites
Layer 2: Site capability mapping
- Confirm GMP compliance of each named site for API and drug product
- Verify quality controls for impurity profile and stability requirements
Layer 3: Throughput and logistics mapping
- Compare manufacturing lead times by dosage form
- Stress-test supply continuity using historical shipment patterns and batch schedules
Key Takeaways
- Abiraterone acetate supply is dominated by a mix of originator ecosystem (Bayer) and major global generics suppliers (e.g., Teva, Viatris, Cipla, Dr. Reddy’s, Sun Pharma, Hikma, Hetero) that support both API and finished dosage pipelines.
- Supplier selection in abiraterone is driven by site-specific GMP readiness, impurity/assay control capability, and batch release performance, not just corporate brand strength.
- A procurement or investment-ready supplier map requires a layered view: regulatory authorization → site capability → throughput/logistics.
FAQs
1) Who is the originator supplier for abiraterone acetate?
Bayer is the originator in the abiraterone acetate commercial ecosystem.
2) Are the major generic companies also involved in abiraterone acetate supply?
Yes. Large generics companies (for example Teva, Viatris, Cipla, Dr. Reddy’s, Sun Pharma, Hikma, and Hetero) participate across API and finished dosage ecosystems in different markets.
3) Is abiraterone acetate supply usually concentrated in a few manufacturers?
Supply is concentrated among a limited set of large API and drug-product capable firms, with additional capacity from regional suppliers depending on filing and market demand.
4) What supplier risks matter most for abiraterone acetate?
Primary risks cluster around GMP site readiness, impurity control reproducibility, and batch release/throughput constraints.
5) What’s the fastest way to reduce supply disruption risk?
Use a supplier strategy that maps multiple authorized sites and validates analytical and release capability, not only corporate contracts.
References
[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Drug products (abiraterone acetate listings and labeling/manufacturer information). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (n.d.). European public assessment reports (EPARs) and product information for abiraterone-containing products. https://www.ema.europa.eu/
[3] World Health Organization. (n.d.). Good manufacturing practices (GMP) and quality assurance guidance relevant to API and finished dosage manufacturing. https://www.who.int/teams/regulation-prequalification/guidance.
